Cooperating in Advanced MRI Technology for Diagnosis and Treatment Planning of Brain Disorders
ELM GROVE, WI / ACCESSWIRE / August 20, 2024 / Prism Clinical Imaging, Inc. (Prism), experts in brain mapping software and applications, and Sora Neuroscience, Inc. (Sora), a brain imaging technology company, today announced a letter of cooperation to assist one another in performing validation testing and commercialization of products for brain resting state functional MRI (rs-fMRI) analysis.
Sora Neuroscience is licensee of a portfolio of resting state network mapping technology developed and clinically investigated at Washington University in St. Louis (WashU) over the past decade. These machine learning algorithms have been trained for brain tumor and epilepsy patient surgery planning. Prism provides clinical software and web-based services for acquisition, analysis, display, and export of functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI), and other data. It also provides tools to combine fMRI and DTI with other imaging such as PET.
These technologies identify critical spatial relationships and functional structures to avoid during treatment, such as surgery.
About Prism Clinical Imaging
Prism Clinical Imaging, Inc., provides clinicians with imaging tools to diagnose and plan treatment for brain disorders including tumors, epilepsy, and other neurological disorders. Deployment options range from on-premises to cloud-based. Please visit www.prismclinical.com for further information. Follow Prism on LinkedIn and Twitter, @PrismClinical.
Contact: James L. Reuss, PhD (CEO), jreuss@prismclinical.com
About Sora Neuroscience, Inc.
Sora Neuroscience, Inc. is a brain imaging technology company committed to providing clinically useful and rigorously tested resting state functional MRI analysis tools ready to be integrated into existing clinical workflows. Sora was founded by leading resting state fMRI innovators at Washington University in St. Louis (WashU) and is headquartered in Minneapolis, Minnesota. For more information, please visit www.soraneuroscience.com.
Contact: Stephen R. Schaefer, JD (CEO), steve@soraneuroscience.com
SOURCE: Prism Clinical Imaging, Inc.
View the original press release on accesswire.com
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…